TxCell announces a temporary partial hold of activities at its pilot manufacturing unit
The decision was made so that TxCell could take action to ensure future compliance with Good Manufacturing Practice (GMP) for the Besançon facility. The manufacturing site in Besançon obtained manufacturing authorization on September 23, 2013 (amended on June 5, 2014) as well as GMP certification on June 10, 2014. This pilot manufacturing unit in Besançon is temporary as TxCell intends to move all production to a new commercial GMP manufacturing facility by 2018.
Specifically, the actions taken by TxCell aim at eliminating the risk of microbial contamination of released drug products. At the current time, no contamination has been found in any product manufactured and released from the TxCell Besançon site.
Manufacturing of new products by TxCell at Besançon will pause until compliance is ensured. TxCell expects to complete this by the end of the summer. TxCell will then demonstrate GMP compliance. This is expected before the end of the year.
Treatment of patients in the CATS29 study (an ongoing phase 2b clinical trial with Ovasave(R) to treat refractory Crohn patients) for whom at least one injection had been given, will continue. This is subject to the implementation of a risk analysis pre-approved by ANSM.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.